Intuitive Surgical (NASDAQ:ISRG) Stock Rating Lowered by Erste Group Bank

Erste Group Bank cut shares of Intuitive Surgical (NASDAQ:ISRG - Free Report) from a strong-buy rating to a hold rating in a report published on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. CICC Research assumed coverage on Intuitive Surgical in a research note on Monday, January 27th. They set a "neutral" rating and a $550.00 price objective on the stock. Barclays boosted their price objective on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Citigroup boosted their price objective on Intuitive Surgical from $640.00 to $711.00 and gave the stock a "buy" rating in a research note on Friday, January 24th. Stifel Nicolaus boosted their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. Finally, Raymond James lifted their target price on Intuitive Surgical from $560.00 to $688.00 and gave the company an "outperform" rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $611.86.

Remove Ads

Intuitive Surgical Trading Up 0.1 %

ISRG traded up $0.68 during trading on Monday, hitting $492.49. The company's stock had a trading volume of 3,367,426 shares, compared to its average volume of 1,456,039. The business's fifty day simple moving average is $562.24 and its 200 day simple moving average is $531.67. The firm has a market capitalization of $175.41 billion, a price-to-earnings ratio of 76.83, a P/E/G ratio of 5.85 and a beta of 1.43. Intuitive Surgical has a twelve month low of $364.17 and a twelve month high of $616.00.

Insiders Place Their Bets

In other Intuitive Surgical news, CFO Jamie Samath sold 269 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00. Following the sale, the chief financial officer now owns 3,282 shares in the company, valued at $1,936,380. This represents a 7.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Amal M. Johnson sold 4,635 shares of the company's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the sale, the director now owns 12,275 shares in the company, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,754 shares of company stock worth $17,691,621 in the last quarter. 0.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Atala Financial Inc acquired a new position in shares of Intuitive Surgical during the 4th quarter worth about $25,000. Hurley Capital LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $28,000. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $26,000. Parvin Asset Management LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $26,000. Finally, BankPlus Trust Department acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $28,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.